what does brca have to do with it? parp inhibitors in ovarian cancer

21

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Upload: thane

Post on 22-Feb-2016

69 views

Category:

Documents

0 download

Report

Download

Tags:

Embed Size (px):

DESCRIPTION

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer. Program Goals. Ovarian Cancer Overview. PARP Inhibition in Ovarian Cancer. Testing for BRCA1/2 Mutations. PARP Inhibitors Under Development. Olaparib in Patients With BRCA1 / BRCA2 Ovarian Cancer. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

What Does BRCA Have to Do With It? PARP Inhibitors in

Ovarian Cancer

Page 2: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Page 3: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Program Goals

Page 4: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Ovarian Cancer Overview

Page 5: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibition in Ovarian Cancer

Page 6: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Testing for BRCA1/2 Mutations

Page 7: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibitors Under Development

Page 8: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Olaparib in Patients With BRCA1/BRCA2 Ovarian Cancer

Page 9: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibitors in Patients With BRCA1/BRCA2 Ovarian Cancer

Page 10: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibitors as Maintenance Therapy

Page 11: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Biomarkers to Measure PARP Inhibitor Response

Page 12: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

PARP Inhibitors and Chemotherapy

Page 13: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Olaparib Maintenance Therapy

Page 14: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Velaparib in Patients With Recurrent Disease

Page 15: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Major Toxicities of PARP Inhibitors

Page 16: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Outstanding Questions

Page 17: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Abbreviations

Page 18: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

References

Page 19: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

References (cont)

Page 20: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

References (cont)

Page 21: What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

References (cont)

The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function

Breast and Ovarian Cancer: Risk Assessment and Prevention ......BRCA mutation Ovarian cancer (any age) Young breast cancer ( < 45 years; < 50 if small family) Multiple cases

DRAFT FoundationFocus CDx BRCA LOH Technical …ovarian cancer patients with deleterious tumor BRCA variants (tBRCA-positive), who may be eligible for treatment with Rubraca (rucaparib)

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer · 2019. 10. 25. · Cancer Syndromes Syndrome Gynecologic Cancer Gene Mutation Breast/Ovarian Cancer Ovary BRCA 1(30-40%risk OC) BRCA 2 (15-25%

HIGHLIGHTS OF PRESCRIBING INFORMATION ... · Study 10 (NCT01482715) and ARIEL2 (NCT01891344), in patients with advanced BRCA-mutant ovarian cancer who had progressed after 2 or more

Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Hereditary Breast and Ovarian Cancer 2015 · 2015-10-21 · Hereditary Breast and Ovarian Cancer 2015 •Among a consecutive series of 11,159 women requesting BRCA testing over one

Molecular Mechanisms of PARP Inhibitors in BRCA …...The wide knowledge of molecular mechanisms in ovarian cancer pathogenesis allowed to identify several molecular targets, thus

Efficacy of PARP Inhibitors in the Treatment of Ovarian …...Review Article 1 Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review Vikas Goswami1

Prophylactic Oophorectomy What is the Effect on Breast and Ovarian Cancer for BRCA Women

Ovarian Cancer Overview for Health Care Providers group · • 2) Site-Specific Ovarian Cancer ... BRCA 1 Hereditary Breast and Ovarian Cancer . ... • RMI= U/S score x menopausal

Hereditary ovarian cancer - CORE · surveillance in high-risk women having a strong family history or BRCA mutation carriers include transvaginal pelvic ultrasound with color Doppler

MOVING FROM PARP INHIBITION TO€¦ · 5 PARP INHIBITION IN THE TREATMENT OF CANCER • Four PARP inhibitors have been approved for use in the treatment of ovarian and breast cancer

UNDERSTANDING GENETICS, BRCA AND PARP INHIBITORS GUIDEBOOK · Understanding Genetics, BRCA and PARP Inhibitors Guidebook 7 result may confirm a diagnosis, indicate that a person is

PARP Inhibitors for Ovarian Cancer · PDF fileAstra Zeneca Pharmaceuticals LP;2017. Rucaparib (Rubraca®)[package insert].Boulder, CO. Clovis ... Dyspnea Photosensitivity ≥ 20% Hypertension

PARP Inhibition Induces Enrichment of DNA Repair Proﬁcient ... · DNA Damage and Repair PARP Inhibition Induces Enrichment of DNA Repair–Proﬁcient CD133 and CD117 Positive Ovarian

Platinum Agents, Taxanes and PARP Inhibitors: The Ovarian ... · other cancers, ovarian cancer harbors its own staging system known as FIGO staging (Table 1). Upon confirmation of

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian … · 2019-01-24 · New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other

PARP Inhibitors for Ovarian Cancer - · PDF fileAstra Zeneca Pharmaceuticals LP;2017. Rucaparib(Rubraca®)[package insert].Boulder, CO. Clovis Oncology, Inc.;2017. ... Dyspnea Rash

BRCA TESTING FOR HEREDITARY BREAST AND/OR OVARIAN CANCER … · mutation testing is recommended if you have any of the following: A personal or family history of breast and/or ovarian

PARP inhibition in ovarian cancer · 2 2 RELEVANT DISCLOSURES •Advisory Boards ( no personal remuneration) for: –AstraZeneca –Clovis –Tesaro •Chief Investigator: ‘AstraZeneca

Significato clinico di BRCA in ovarian cancermedia.aiom.it/userfiles/files/doc/AIOM-Servizi/slide/20160615RM_32... · Sistema nervoso centrale (6%) Ovaio (7%) Stomaco (6%) 70000 donne

Original article: INDUCTION OF APOPTOSIS AND ......vealed that cells deficient in breast cancer sus-ceptibility proteins (BRCA) are 100- to 1000-fold more sensitive to PARP inhibition

Ovarian Cancer Awareness Month...2007/04/09 · 6 + #OvarianCancer Risk Factors Family history - Approximately 15% of ovarian cancer cases are due to the BRCA or other gene mutations

Update on PARP inhibitors: opportunities and challenges in ... · carcinoma ovarico “platino sensibile” con mutazioni germinali o somatiche di BRCA . Can PARP inhibitors replace

EP-100 sensitizes BRCA wild-type ovarian cancer cells to

Impact - greenslopesgynaecology.com · BRCA ovarian cancers are exclusively epithelial, mostly high grade serous or undifferentiated Borderline and mucinous tumors have not been observed

PARP Inhibitor Olaparib in BRCA-Deﬁcient Advanced Ovarian … · 2009. 8. 20. · \ { h{ {w y~j f wy y{Dy EKc` Y PARP Inhibitor Olaparib in BRCA-Deﬁcient Advanced Ovarian Cancer

ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to ......ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status Catherine J. Huntoon1,

PARP Inhibitors for the Management of Ovarian Cancer

Meet The Professorsimages.researchtopractice.com/2020/Meetings/Slides/... · Agenda Part 1: PARP Inhibitors in Ovarian Cancer • 58-year-old woman: BRCA1 exon 3 deletion germline

Ovarian Cancer Genetics and Risk Reducing Surgery · •14% had BRCA mutation •17% of patients with HGSOC had germline BRCA mutation •44% of those with BRCA mutation had no reported

CTLA-4 Blockade Synergizes Therapeutically with …...Research Article CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deﬁcient Ovarian Cancer Tomoe Higuchi1,

BRCA 1/2 · 2020-05-04 · 3 BRCA1/2 are a key factor in breast and ovarian cancer development Breast and ovarian cancers are common, they are the first and fifth most common cancers